Campaign for Access to Essential Medicines
3626760
215508676
2008-05-28T14:46:26Z
DOI bot
6652755
Citation maintenance. You can [[WP:DOI|use this bot]] yourself! Please [[User:DOI_bot/bugs|report any bugs]].
The '''Campaign for Access to Essential Medicines''' is an international campaign started by [[Médecins Sans Frontières]] to increase the availability of "essential medicines" in [[developing country|developing countries]]. [[Infectious disease]]s like [[malaria]], [[sleeping sickness]] and [[tuberculosis]], all of which are uncommon in developed countries, can be effectively treated with certain [[Medication|drug]]s (the "essential medicines"), but these drugs are usually very expensive, out of production or little understood.
The lack of research into diseases that affect most of the world’s poor population is known as the [[10-90 gap]] and it occurs because [[pharmaceutical company|pharmaceutical companies]] rarely make a profit when developing drugs for these diseases. Although some countries have created legislation to encourage development of "essential medicines," which are called [[orphan drug]]s in the [[United States]], MSF started this campaign in November [[1999]] to bring more awareness to the issue {{ref_label|accessmed|1|a}}, and used its prize money from its 1999 [[Nobel Peace Prize]] to fund the project {{ref_label|funding|2|a}}.
==HIV/AIDS==
[[HIV/AIDS]] is one major target for this campaign, since the vast majority of those infected live in poor, developing countries, specifically [[sub-Saharan Africa]] (see [[AIDS in Africa]]), which has 25.4 million people living with HIV, out of a worldwide total of 39.4 million (2004) {{ref_label|HIV_stats|3|a}}. The campaign pushes [[generic drug|generic production]] of [[antiretroviral drug]]s for treatment of AIDS patients, and it also helps victims pressure their governments to force drug companies to lower their prices. In 2001, MSF mediated an agreement with the Brazilian Ministry of Health, as well as Fiocruz and FarManguinhos (research and drug production companies, respectively) to produce generic antiretroviral drugs at an affordable price for use in poor countries {{ref_label|fiocruz|4|a}}.
==Malaria==
[[Malaria]] is another major disease faced by sub-Saharan Africa, which sees 90% of the world-wide deaths due to malaria. Although malaria patients do have access to fairly cheap drugs, such as [[chloroquine]] and sulphadoxine-pyrimethamine, strains of malaria have developed resistance to these drugs in many severely affected areas {{ref_label|malaria|5|a}}. MSF is pressuring governments to fund the development of [[Artemisinin|artemisinin-based combination therapy]] (ACT), which has been shown to be extremely effective {{ref_label|ACT|6|a}}{{ref_label|malaria_drugs|7|a}}.
==Leishmaniasis==
[[Leishmaniasis]] is extremely rare in the developed world but often occurs [[epidemic]]ally in poor countries, such as [[Sudan]] and [[Demographics_of_Bangladesh#HIV.2FAIDS|Bangladesh]]. It receives very little international attention, but occurs in four different forms ([[Visceral leishmaniasis|VL (kala azar)]], [[Cutaneous leishmaniasis|CL]], [[Mucocutaneous leishmaniasis|MCL]], [[Diffuse cutaneous leishmaniasis|DCL]]), three of which are very difficult to treat (VL, MCL, DCL), especially when they occur in combination with HIV infection {{ref_label|kalaazar|8|a}}. Cheaply available drugs include [[Antimony|pentavalent antimony]] ([[sodium stibogluconate]]), but although effective in some areas, resistance to this drug is increasing, and MSF is pressuring drug companies to increase research and development into new therapies.
==Sleeping sickness==
[[Sleeping sickness]] (human African trypanosomiasis) is currently occurring epidemically in [[Angola]], the [[Democratic Republic of the Congo]] and Sudan, but is common in the rest of Africa as well {{ref_label|ss1|9|a}}. For advanced cases of the disease, the only available treatment is often [[melarsoprol]], which is extremely dangerous, and increasingly ineffective. In 2000, MSF began a major effort to pressure drug companies to increase research and development for [[eflornithine]] and [[nifurtimox]] as treatments for the disease {{ref_label|ss2|10|a}}.
==Other diseases==
[[Meningococcal meningitis]] epidemics can be largely controlled by large-scale [[Meningitis#Vaccination|vaccinations]] when a few cases are detected, meaning that expensive, massive stockpiles of [[vaccine]]s must be kept on hand during epidemic seasons {{ref_label|men1|11|a}}. MSF and the [[World Health Organisation]] are negotiating with drug companies to lower costs of vaccines, and to increase research into long-term immunization and drugs for treatment {{ref_label|men2|12|a}}.
[[Tuberculosis]], although largely unknown in the developed world, kills millions of people in sub-Saharan Africa and [[southeast Asia]] {{ref_label|tb1|13|a}}. [[Tuberculosis#Prevention|Vaccine]] and drug therapy exist for [[tuberculosis treatment]], but these drugs are decades old, and MSF is trying to increase research into new vaccines, as well as lower the price for treatment of multiple drug resistant tuberculosis (MDR-TB). The current drug therapy, involving diligent dosage of [[isoniazid]], [[rifampicin]], [[ethambutol]], and [[pyrazinamide]], is difficult for patients to follow, leading to more cases of MDR-TB when patients don’t finish their treatment {{ref_label|tb2|14|a}}.
Other conditions, such as [[Buruli ulcer]], must be treated with [[surgery]] for excision of the infected part {{ref_label|buruli|15|a}}. [[Trachoma]] must be treated with a combination of surgery (if [[trichiasis]] has occurred) and complicated [[tetracycline]] treatment {{ref_label|trachoma|16|a}}. Many of these diseases, such as tuberculosis, occur with HIV infection as [[opportunistic infection]]s, complicating treatment further.
==See also==
* [[Essential medicines]]
* [[World Health Organization]]
** [[Department of Essential Drugs and Medicines]]
** [[WHO Model List of Essential Medicines]]
* [[Universities Allied for Essential Medicines]]
==References==
#{{note|accessmeda}} [http://www.accessmed-msf.org/campaign/campaign.shtm The Campaign Background]. ''MSF Access Website''. Retrieved Dec. 22, 2005.
#{{note|fundinga}} MSF Article (2000). [http://www.msf.org/msfinternational/invoke.cfm?component=article&objectid=C7922C74-18F8-4205-93DD6E5FCCA4B2FE&method=full_html Nobel funds allocated to neglected diseases]. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|HIV_statsa}} WHO (2004). [http://www.unaids.org/wad2004/EPIupdate2004_html_en/Epi04_03_en.htm#P28_3962 Introduction]. ''AIDS epidemic update: December 2004''. Retrieved Dec. 22, 2005.
#{{note|fiocruza}} MSF Article (2002). [http://www.msf.org/msfinternational/invoke.cfm?component=article&objectid=F8557436-9B60-4D00-BC5F0476D8B7A5E1&method=full_html Brazilian generic drugs in South Africa]. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|malariaa}} Roll Back Malaria. [http://www.rbm.who.int/cmc_upload/0/000/015/370/RBMInfosheet_3.htm Malaria in Africa]. ''WHO''. Retrieved Dec. 22, 2005.
#{{note|ACT_a}}*{{cite journal
|author=Mutabingwa TK
|title=Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
|journal=Acta Trop
|year=2005
|volume=95
|issue=3
|pages= 305–315
|doi=10.1016/j.actatropica.2005.06.009}}
#{{note|malaria_drugsa}} MSF Article (2003). [http://www.msf.org/msfinternational/invoke.cfm?component=article&objectid=1CAEF290-94D4-4775-B4030CB4FE65AC54&method=full_html Africa 'needs better malaria drugs']. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|kalaazara}} MSF Fact Sheet (2004). [http://www.accessmed-msf.org/documents/kalaazarfactsheet.pdf Leishmanisasis]. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|ss1a}} WHO Fact Sheet (2001). [http://www.who.int/mediacentre/factsheets/fs259/en/ African trypanosomiasis or sleeping sickness]. ''WHO''. Retrieved Dec. 22, 2005.
#{{note|ss2a}} MSF Fact Sheet (2004). [http://www.accessmed-msf.org/documents/ssfactsheet.pdf Sleeping sickness or human African trypanosomiasis]. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|men1a}} MSF Article (2001). [http://www.msf.org/msfinternational/invoke.cfm?component=article&objectid=61FD4B2C-5E5A-4776-B8076EC3A57ACEE4&method=full_html Meningitis definition and treatment]. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|men2a}} MSF Fact Sheet (2004). [http://www.accessmed-msf.org/documents/menfactsheet.pdf Meningococcal meningitis].
#{{note|tb1a}} The Campaign [http://www.accessmed-msf.org/campaign/tb01.shtm Tuberculosis]. ''MSF''. Retrieved Dec. 22, 2005.
#{{note|tb2a}} Division of Tuberculosis Elimination (2003) [http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250111.htm Treatment of Drug-Susceptible Tuberculosis Disease in Persons Not Infected with HIV] '''CDC'''. Retrieved Dec. 22, 2005.
#{{note|burulia}} MSF Article (2002) [http://www.msf.org/msfinternational/invoke.cfm?component=article&objectid=E551B65F-997A-42E4-8B83192BD22C4C17&method=full_html MSF starts Buruli's ulcer project in Cameroon] '''MSF'''. Retrieved Dec. 22, 2005.
#{{note|trachomaa}} The Campaign [http://www.accessmed-msf.org/campaign/other.shtm Trachoma] '''MSF'''. Retrieved Dec. 22, 2005.
==External links==
*[http://www.accessmeds.org/ Accessmeds.org - Essential medicines right campaign]
*[http://www.accessmed-msf.org/ MSF Campaign website]
*[http://www.who.int/topics/essential_medicines/en/ WHO Essential Medicines website]
*[http://www.eldis.org/healthsystems/access/index.htm Access to medicines and international issues] from the Health Systems Resource Guide
[[Category:Charities based in France]]
[[Category:International charities]]
[[Category:Health charities]]
[[Category:Malaria]]
[[Category:Tuberculosis]]